Bristol-Myers Squibb Company (NYSE: BMY) is -6.74% lower on its value in year-to-date trading and has touched a low of $65.28 and a high of $81.43 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The BMY stock was last observed hovering at around $67.48 in the last trading session, with the day’s loss setting it -0.38% off its average median price target of $81.50 for the next 12 months. It is also 29.37% off the consensus price target high of $95.00 offered by 21 analysts, but current levels are -8.23% lower than the price target low of $62.00 for the same period.
Currently trading at $67.10, the stock is -2.80% and -5.78% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 10.03 million and changing -0.56% at the moment leaves the stock -8.70% off its SMA200. BMY registered -3.80% loss for a year compared to 6-month gain of -4.78%.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
The stock witnessed a -7.13% loss in the last 1 month and extending the period to 3 months gives it a -13.25%, and is 0.89% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 2.44% over the week and 1.78% over the month.
Bristol-Myers Squibb Company (BMY) has around 34300 employees, a market worth around $142.54B and $46.16B in sales. Current P/E ratio is 22.73 and Fwd P/E is 8.18. Profit margin for the company is 13.70%. Distance from 52-week low is 2.80% and -17.60% from its 52-week high. The company has generated returns on investments over the last 12 months (11.80%).
Bristol-Myers Squibb Company (BMY) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Bristol-Myers Squibb Company (BMY) is a “Overweight”. 21 analysts offering their recommendations for the stock have an average rating of 2.40, where 10 rate it as a Hold and 1 think it is a “Overweight”. 9 of the analysts rate the stock as a “Buy”. 1 analysts have rated the stock as a Sell or Underperform.
Bristol-Myers Squibb Company is expected to release its quarterly report on 04/27/2023.The EPS is expected to shrink by -5.40% this year
Bristol-Myers Squibb Company (BMY) Top Institutional Holders
The shares outstanding are 2.11B, and float is at 2.10B with Short Float at 0.81%.
Bristol-Myers Squibb Company (BMY) Insider Activity
A total of 18 insider transactions have happened at Bristol-Myers Squibb Company (BMY) in the last six months, with sales accounting for 9 and purchases happening 9 times. The most recent transaction is an insider sale by Caforio Giovanni, the company’s Board Chair and CEO. SEC filings show that Caforio Giovanni sold 240,000 shares of the company’s common stock on Feb 06 at a price of $74.65 per share for a total of $17.92 million. Following the sale, the insider now owns 0.24 million shares.
Bristol-Myers Squibb Company disclosed in a document filed with the SEC on Feb 06 that Powell Ann (EVP, Chief Human Resources) sold a total of 11,183 shares of the company’s common stock. The trade occurred on Feb 06 and was made at $74.69 per share for $0.84 million. Following the transaction, the insider now directly holds 23043.0 shares of the BMY stock.
Still, SEC filings show that on Nov 09, Powell Ann (EVP, Chief Human Resources) disposed off 16,250 shares at an average price of $80.45 for $1.31 million. The insider now directly holds 34,226 shares of Bristol-Myers Squibb Company (BMY).
Bristol-Myers Squibb Company (BMY): Who are the competitors?
The company’s main competitors (and peers) include Johnson & Johnson (JNJ) that is trading -12.55% down over the past 12 months and Pfizer Inc. (PFE) that is -22.68% lower over the same period. Abbott Laboratories (ABT) is -15.70% down on the 1-year trading charts.